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Several studies report a higher rate of papillary thyroid carcinomas (PTC) in patients with Hashi-
moto thyroiditis (HT), indicating a possible correlation between the two diseases. We studied a
group of 89 subjects undergoing surgery for thyroid carcinomas compared with a control group of
89 subjects operated on for normofunctioning goiter, and a second group of 47 patients under-
going total thyroidectomy for HT. Association with HT was found in 19 of the 71 PTC subjects
(26.7%) and in 8 goiter patients (8.9%), which was a significant difference (P < 0.02). Thirteen of
the HT patients, mostly with the nodular form, showed coexistent PTC (27.6%). HT and PTC
coexisted in several morphological, immunohistochemical, and biomolecular aspects; increased
incidence of PTC in HT patients might therefore indicate that HT is a precursor of thyroid cancer.
Further studies are required, however, in order to confirm this hypothesis; until then, HT patients
should undergo careful clinical and technical follow-up.
H ASHIMOTO THYROIDITIS (HT), described for the firsttime in 1912,1 is an autoimmune disease, affect-
ing 5 per cent of the general population; it involves
widespread lymphocyte infiltration, fibrosis, and pa-
renchymal atrophy. It is about 15 times more common
in women than in men and is generally diagnosed
in subjects from 30 to 50 years of age. More than
90 per cent of such cases show high antiperoxidase
and antithyroglobulin antibody titers.2
HT occurs in two different clinical forms: nodular
or diffuse. Treatment is almost always medical, espe-
cially in patients with hypo- or hyperthyroidism.
Surgery is indicated in patients when an increase in
glandular volume causes compressive symptoms,
when drug therapy has proved to be unsatisfactory,
and, above all, when there is suspected neoplastic de-
generation of one or more nodules.
The association between HT and PTC was first de-
scribed by Dailey et al. in 1955.3 Since then, numerous
authors4–7 have reported a coexistence between the
two diseases. Nevertheless, although these two dis-
eases of the thyroid have a great many morphological,
immunohistochemical, and, even more important,
biomolecular features in common, the pathological
significance and possible clinical implications of
the correlation between them are still not fully under-
stood.
Patients and Methods
The aim of our study was to evaluate the correlation
between HT and PTC. We performed a retrospective
analysis of two groups; the first was made up of 89
patients who had undergone total thyroidectomy for
carcinomas of the thyroid and the second of 47 sub-
jects who had undergone total thyroidectomy after a
preoperative diagnosis of HT. These two groups were
part of a wider series of 1,012 patients who underwent
thyroidectomy in our division from January 1993 to
December 2003. In all cases, the preoperative diag-
nostic workup included a thyroid hormone assay, ul-
trasound and scintigraphic examinations of the thy-
roid, and a cytological examination of the gland by
means of echo-guided FNA; the clinical diagnosis of
HT was based on the increase of serum levels of an-
tiperoxidase, antimicrosome and antithyroglobulin
antibodies.
Group 1
Of the 89 patients who had undergone surgery for
carcinomas of the thyroid, 68 were women and 21
were men, with a mean age of 47 years (range, 21 to
77). Seventy-one (79, 8%) of these were papillary car-
cinomas (PTC), 12 of which were occult, seven (7,
8%) follicular carcinomas, three (3, 3%) anaplastic
carcinomas, four (4, 5%) medullary carcinomas, two
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(2, 2%) insular carcinomas, and two (2, 2%) oncocyte
carcinomas. This group of patients was compared with
a similar group of 89 patients of the same sex and age
who had undergone surgery for normofunctioning
nodular goiter during the same period.
Group 2
Of the 47 patients undergoing radical thyroidectomy
after a preoperative diagnosis of HT, 44 were women
and 3 were men, with a mean age of 44.7 years (range,
20 to 65). Nineteen cases (40.4%) were nodular HT,
23 (48.9%) were diffuse, and 5 (10.6%) were in pa-
tients with normofunctioning goiter who had already
been followed up for some time. Of the 19 patients with
nodular HT, surgical treatment was chosen in 8 be-
cause the FNA results produced a cytological indica-
tion of carcinomas, in 10 patients because one or more
nodules had increased in volume, and in 1 patient be-
cause of the appearance of compressive symptoms. Of
the 23 patients with diffuse HT and the 5 with HT
developing on a preexistent goiter, 25 underwent sur-
gery because of compressive symptoms and 3 patients
with an associated hyperthyroidism underwent sur-
gery, because of insufficient response to drug therapy.
In all these patients, total thyroidectomy was per-
formed. The histopathological diagnosis of HT was
based on the presence of diffuse, chronic, inflamma-
tory infiltrate containing lymphocytes, germinative
plasma cells and centers, fibrosis, and thyroid cells
enlarged with eosinophilic cytoplasm and a large num-
ber of mitochondria.
Results
Group 1
Of the 89 patients operated on for thyroid carcino-
mas, histological examination of the gland showed the
concomitant presence of a histopathological picture
suggesting HT. This was observed only in the 71 pa-
tients with PTC, with an incidence rate of association
between HT and PTC of 26.7 per cent. In one patient
(1.4%), the PTC was associated with Basedow disease
and in one (1.4%) with multinodular hyperfunctioning
goiter; in the remaining 50 patients, the PTC either
presented as a single nodule or else was associated
with a histopathological picture indicating goiter
(70.4%).
In the control group, made up of 89 patients oper-
ated on in the same period for normofunctioning nodu-
lar goiter, only in 8 cases (8.9%) did we observe the
concomitant presence of histopathological pictures
suggesting HT.
The association between HT and PTC, therefore,
was significantly higher in the group of patients who
had undergone surgery for thyroid carcinomas than in
those operated on for goiter (P < 0.02) (Table 1).
Group 2
Of the 47 patients who underwent total thyroidec-
tomy after a diagnosis of HT, histological examination
produced a diagnosis of differentiated carcinomas of
the thyroid in 13 patients (27.6%), which in all cases
proved to be PTC, with a mean diameter of 9.6 mm
(range, 1 to 25 mm); in no case was a laterocervical
lymphoadenopathy present. PTC was found in 11 of
the 19 patients (57.9%) affected by nodular HT (4
involving an occult tumor) and 2 (8.7%) of the 23
patients with diffuse HT (in both these patients the
carcinoma was occult). No case of PTC was found in
the group of 5 patients in whom the HT had developed
on a preexistent nodular goiter.
In the remaining 34 patients operated on for HT,
2 cases (6.1%) showed an association between micro-
follicular adenoma while 5 cases (15.2%) showed co-
existent histopathological results indicating goiter.
It is interesting to note that 11 of the 13 cases of
PTC (84.6%) were found in patients with nodular HT,
and only 2 (15.4%) in the patients with diffuse HT
(P < 0.001), indicating a significantly higher risk of
the development of PTC on the nodular variant of HT.
The sex and age of the patients nor the time lapse
TABLE 1. Hashimoto’s Thyroiditis Coexistent with PTC
(Group 1)
PTC Goiter P
Coexistent 26.7%
(19/71 patients)
8.9%
(8/89 patients)
<0.02
PTC, papillary thyroid carcinoma.
TABLE 2. Hashimoto’s Thyroiditis Coexistent with PTC (Group 2)
HT Nodular Variant HT Diffuse Variant P
Coexistent PTC 84.6 (11/13 PTC) 15.4% (2/13 PTC) <0.001
Coexistent HT and PTC HT P
Mean age 45.7 46.1
M/F ratio 1/12 2/22 NS
Time lapse between HT diagnosis and surgery 22.9 mesi (range, 0–96) 32.1 mesi (range, 0–123)
HT, Hashimoto thyroiditis; PTC, papillary thyroid carcinoma; NS, not significant.
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occurring between the diagnosis of HT and surgery
seemed to be at all significant. In fact, in the group of
13 patients with an association between HT and PTC,
the male/female ratio was 1:12 and the mean age was
45 years, while in the 34 patients in whom HT was not
associated with PTC, the male/female ratio was 2:22
and the mean age was 44.5 years. In the patients op-
erated on for HT associated with PTC, the HT diag-
nosis had been made on average 22.9 months before
surgery (range, 0 to 96 months), whereas in the pa-
tients with HT not associated with PTC, the diagnosis
of HT had been made on average 32.1 months before
surgery (range, 0 to 123 months).
None of the 11 patients with PTC proved to have a
laterocervical lymphoadenopathy. The mean follow-
up of patients diagnosed with PTC was 56.7 months
(range, 6 to 102 months); during this period no neo-
plastic relapse was observed (Table 2).
Discussion
An association between HT and differentiated thy-
roid carcinomas has been reported by several authors
from the 1950s up to the present time, although with
various incidence rates, probably due not only to the
different genetic and environmental factors involved,
but above all to the various anatomopathological defi-
nitions of HT used in the different studies (Table 3).
The aim of our own study was to verify the asso-
ciation between HT and PTC by evaluating two series
of patients operated on in our institute from 1993 to
2003. In the first series, we compared the different rate
of histopathological pictures indicating HT found in
patients operated on for thyroid carcinomas and in a
control group made up of patients who had undergone
surgery for normofunctioning goiter. In the second se-
ries of patients, we evaluated the incidence rate of
PTC found in patients operated on after a preoperative
diagnosis of HT.
Association with HT was observed in 19 of 71 pa-
tients (26.7%) who underwent surgery for PTC, and in
only 8 of 89 patients (8.9%) operated on for thyroid-
ectomy for normofunctioning nodular goiter; in agree-
ment with the results reported by several other au-
thors,18–21 this confirmed the suggestion that there
was a significantly higher association with HT in pa-
tients operated on for PTC than in those undergoing
surgery for goiter (P < 0.02).
A meta-analysis conducted by Singh et al.2 demon-
strated that the incidence rate of HT is 2.77 times
higher in PTC patients than in subjects affected by
benign thyroid diseases. Furthermore, in patients with
thyroid carcinomas, the incidence rate of association
with HT is 1.99 times higher in those with PTC than in
subjects with other histopathological forms of thyroid
carcinomas, although indirectly, these results suggest
that patients with HT might well present a stronger
predisposition towards the development of PTC.
This hypothesis is reinforced by the fact that a large
number of biomolecular studies have shown the
presence of mutation products of the oncogens
RET/PTC—a specific genetic alteration for PTC—in
patients with HT but without clinically manifest
tumors.22, 23
Several studies involving the expression of p63 pro-
teins, which generally intervene in the differentiation
processes of the stem cells and which are not present
in normal thyroid tissue, have shown a higher expres-
sion of such proteins in a great many cases both of HT
and of PTC, which is a further indication that there is
most probably a link between the two diseases.24
Moreover, several other studies have shown the
presence of both lymphocyte infiltrate and of classical
HT in association with 30 per cent to 58 per cent of
PTC cases and only in 20 per cent of follicular carci-
nomas and in 14 per cent of follicular adeno-
mas.17, 25, 26 These data are a further confirmation of
the hypothesis that PTC pathogenesis involves an au-
toimmunity mechanism stimulated by lymphocyte in-
filtration of the thyroid gland tissue. Furthermore, sev-
eral studies regarding the effects of certain factors
such as race and sex on the presence of lymphocyte
infiltrate in PTC, indicative of autoimmune thyroiditis,
have shown that this is significantly higher in Japanese
patients of both sexes and in both white and black
American women with PTC than in the same popula-
tions affected by multinodular goiter and follicular ad-
enomas.27 This result is in agreement with several epi-
demiological data that report a higher rate, not only of
TABLE 3. Hashimoto’s Thyroiditis Coexistent with
Thyroid Carcinoma
Authors
Coexistent HT
and PTC (%)
Dailey et al. 19553 17.7
Pollock and Sprong 19586 9.6
Meier et al. 19598 1
Woolner et al. 19597 3
Schlicke et al. 19609 8.7
Shands 196010 7
Chesky et al. 196211 11.1
Crile and Hazard 196212 0.5
Hirabayashi and Lindsay 19654 22.5
Holmes et al. 19775 8.3
Figg et al. 197813 19
Ott et al. 198514 32
Sclafani et al. 199315 17
Loh et al. 199916 20.3
Singh et al. 19992 15
Kebebew et al. 200117 30
HT, Hashimoto thyroiditis; PTC, papillary thyroid carci-
noma.
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HT, but also a predominance of PTC associated with
HT, in women than in men.9, 11, 14, 16, 18
With regard to their clinical course, thyroid tumors
associated with HT do not seem to be any more ag-
gressive than nonassociated forms. In the series stud-
ied by Eisenberg et al.,19 none of the patients diag-
nosed with an association between a thyroid
carcinoma and HT developed either disease relapse or
metastases during the mean follow-up period of 74
months. In our own cases, with a mean follow-up of
56.7 months (range, 6 to 102 months), there was no
disease relapse in any of the 19 patients with concomi-
tant HT and PTC or in the 13 subjects operated on for
HT when papillary carcinomas were was found.
Ott et al.14 reported that carcinomas of the thyroid
were found in 47 (32%) of 146 patients who had un-
dergone surgery for HT associated with a solitary cold
nodule of the thyroid gland. McKee et al.28 performed
histological analysis in 27 of 115 patients with a di-
agnosis of HT and found 12 cases of concomitant
thyroid cancers (10%), made up of four papillary car-
cinomas, one follicular carcinoma, and 7 thyroid lym-
phomas.
In our study, we found an association between HT
and thyroid carcinomas, all PTCs, in 13 of 46 patients
(28.2%) who had undergone thyroidectomy with a
preoperative diagnosis of HT. We did not observe any
significant differences with regard to age, sex, and the
time lapse from the diagnosis of HT until the moment
of surgery between these 13 patients and the remaining
33 subjects. An important correlation, however,
seemed to exist between the nodular variant of HT and
PTC. We found, in fact, that 11 of the 13 papillary
carcinomas (84.6%) were in patients with this form
of HT, while only in 2 patients (15.4%) was this type
of carcinoma present in patients with diffuse HT.
Analysis of this result indicates a much higher risk of
the development of PTC in subjects with nodular HT
(P < 0.001).
In conclusion, therefore, the increased incidence re-
ported in literature of thyroid carcinomas on the nodu-
lar form of HT suggests that HT might well be con-
sidered as a precursor of the disease.15, 28, 29 The
majority of such tumors are PTCs, although an asso-
ciation with follicular, indifferentiated, or medullary
carcinomas has also frequently been reported.4, 11, 15
Furthermore, PTC and HT have several morphologi-
cal, immunohistochemical, and, even more important,
biomolecular features in common. Although HT is a
benign disease, it may represent the site of RET/PTC
rearrangements, an early, but extremely specific
marker associated with PTC.
On the basis of these considerations, therefore,
should HT be deemed a submicroscopic homologue of
PTC? Is there any possibility of establishing a valid
criterion for the selection of those patients with HT at
higher risk of developing thyroid carcinomas? So far,
there are no answers to these questions; there is no
doubt that further studies and research are necessary in
order to establish the predictive value of RET/PTC
rearrangement and of several other markers coexisting
in patients with HT, PTC, and other forms of thyroid
cancers. Since, however, the annual incidence of car-
cinomas of the thyroid is 1 male and 2.6 females per
100,000 subjects, extremely long trials involving an
enormous number of patients29 would therefore be in-
volved.
At the present time, the only possible approach con-
sists in careful, accurate follow-up of HT patients, and
especially those with the nodular variant of the dis-
ease, not only from the clinical point of view, but
above all, with cytological examination of the nodules.
The surgical approach should always implicate total
thyroidectomy, since it has been reported20 that cases
of PTC associated with HT are much more frequently
multicentric (93%) than the nonassociated form of
PTC (50%).
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